Novo Nordisk A S (NVO) stock
NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Score 4/30
$39.43−1.27 (-3.12%)
Close on Nov 18, 2026Market cap $176.06BP/E 11.6Yield –
Novo Nordisk A S operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was 119.10B DKK, down 1.5% from the year before. Over ten years it grew 12.0% a year on average. The highest annual figure on record is 120.97B DKK in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 119.10B DKK | -1.5% |
| FY2024 | Dec 31, 2024 | 120.97B DKK | +11.1% |
| FY2023 | Dec 31, 2023 | 108.91B DKK | +38.1% |
| FY2022 | Dec 31, 2022 | 78.89B DKK | +43.4% |
| FY2021 | Dec 31, 2021 | 55.00B DKK | +5.9% |
| FY2020 | Dec 31, 2020 | 51.95B DKK | +11.0% |
| FY2019 | Dec 31, 2019 | 46.78B DKK | +4.9% |
| FY2018 | Dec 31, 2018 | 44.62B DKK | +8.4% |
| FY2017 | Dec 31, 2017 | 41.17B DKK | -14.8% |
| FY2016 | Dec 31, 2016 | 48.31B DKK | +26.2% |
| FY2015 | Dec 31, 2015 | 38.29B DKK | – |
See a number that looks wrong?